Trial Profile
Effects of BACE Inhibitor (verubecestat) in a significant reduction of Aβ oligomers in cerebrospinal fluid in healthy male subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2017
Price :
$35
*
At a glance
- Drugs Verubecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- 24 Aug 2017 New trial record
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017